vTv Therapeutics Business Summary

vTv Therapeutics Inc. (VTVT) is a late-stage clinical biopharmaceutical company that operates primarily through a research and development model focused on oral, small molecule drug candidates for metabolic and inflammatory diseases. The company generates revenue through strategic licensing agreements, milestone payments, and potential future commercialization of its pipeline. Its primary business segment is centered on its lead asset, cadisegliatin (TTP399), a first-in-class liver-selective glucokinase activator currently in Phase 3 clinical trials (CATT1) as an adjunctive therapy to insulin for Type 1 Diabetes (T1D). In February 2026, the company further diversified its revenue stream by amending its global licensing agreement with Newsoara Biopharma for its PDE4 inhibitor, HPP737, securing a $20 million upfront payment. vTv Therapeutics competes directly with major pharmaceutical players in the diabetes space, including AstraZeneca (Farxiga), Lexicon Pharmaceuticals (Zynquista), Eli Lilly, and Novo Nordisk, positioning itself as a niche leader in developing insulin-independent oral therapies designed to reduce hypoglycemic events. The company is led by Chairman, President, and CEO Paul Sekhri, a veteran life sciences executive with over 35 years of experience who previously served as CEO of eGenesis and Lycera, and held senior leadership roles at Sanofi, Teva, and Novartis. The executive team includes Executive Vice President and CFO Michael Tung, M.D., MBA, who joined in 2025 with extensive experience in healthcare investment and corporate strategy, and Chief Medical Officer Thomas Strack, M.D., a specialist in metabolic clinical development. vTv is backed by a high-pedigree board and investor base, including Ronald Perelman’s MacAndrews & Forbes, Samsara BioCapital (represented by Dr. Srinivas Akkaraju), and the T1D Fund (Breakthrough T1D Venture). Other notable institutional investors include Baker Bros. Advisors and FMR LLC, providing the company with significant capital to fund its late-stage clinical programs through anticipated 2026 data readouts.